See more : Torq Resources Inc. (TRBMF) Income Statement Analysis – Financial Results
Complete financial analysis of Marker Therapeutics, Inc. (MRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marker Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Euroespes, S.A. (EEP.MC) Income Statement Analysis – Financial Results
- Ambuja Cements Limited (AMBUJACEM.NS) Income Statement Analysis – Financial Results
- Hello Group Inc. (1MO.F) Income Statement Analysis – Financial Results
- Phyto Chem (India) Limited (PHYTO.BO) Income Statement Analysis – Financial Results
- Veralto Corporation (VLTO) Income Statement Analysis – Financial Results
Marker Therapeutics, Inc. (MRKR)
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31M | 9.00M | 1.24M | 466.79K | 213.19K | 205.99K | 183.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.05K | 120.72K |
| Cost of Revenue | 10.42M | 3.68M | 3.16M | 18.88M | 12.76M | 124.00M | 5.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.63K | 38.60K |
| Gross Profit | -7.11M | 5.32M | -1.92M | -18.41M | -12.55M | -123.79M | -5.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.42K | 82.12K |
| Gross Profit Ratio | -214.60% | 59.13% | -154.70% | -3,944.85% | -5,887.41% | -60,094.84% | -2,768.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 89.50% | 68.03% |
| Research & Development | 10.42M | 26.14M | 27.79M | 18.88M | 12.76M | 124.00M | 5.25M | 3.80M | 1.71M | 189.00K | 661.63K | 1.06M | 203.73K | 290.05K | 93.04K | 182.34K | 425.57K | 173.17K | 248.36K | 1.04M | 1.73M | 833.59K | 0.00 | 341.19K | 294.92K |
| General & Administrative | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Other Expenses | 0.00 | -232.97K | -2.41M | 0.00 | 0.00 | 116.05M | -183.06K | 1.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.74K | 7.48K | 5.97K | 6.37K | 147.53K | 37.45K | 42.37K | 40.77K | 0.00 | 20.64K | 17.71K |
| Operating Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.15M |
| Cost & Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.19M |
| Interest Income | 539.16K | 248.06K | 5.70K | 148.74K | 1.08M | 253.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.81K | 0.00 | 0.00 | 0.00 | 3.96K | 0.00 | 0.00 | 125.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.93K | 575.54K | 1.76M | 745.07K | 679.33K | 1.24M | 1.19M | 778.18K | 1.38M | 446.60K | 116.82K | 0.00 | -5.78M | -2.28M | -379.86K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.79M | 3.68M | 3.16M | 1.08M | 286.58K | 148.17M | 11.48M | 8.49M | -27.90M | -26.94M | -466.28K | 1.11M | 1.29M | 93.84K | 3.74K | 7.48K | 5.97K | 6.37K | 71.51K | 37.45K | 42.37K | 40.89K | -4.68K | 20.64K | 17.71K |
| EBITDA | -11.79M | -19.79M | -36.32M | -27.63M | -22.03M | -147.97M | -11.30M | 6.04M | -34.06M | -30.31M | -3.78M | -5.58M | 0.00 | -3.85M | -3.27M | -1.41M | -2.51M | -851.42K | -838.07K | -2.65M | -5.74M | -2.24M | -379.86K | -457.20K | -1.05M |
| EBITDA Ratio | -356.14% | -291.69% | -2,924.62% | -5,964.44% | -10,441.30% | -71,910.65% | -6,543.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,476.07% | -815.17% |
| Operating Income | -14.58M | -29.95M | -39.48M | -28.89M | -22.53M | -148.17M | -11.66M | -8.49M | -6.16M | -3.37M | -3.31M | -6.22M | -2.64M | -3.94M | -5.38M | -2.28M | -2.51M | -888.25K | -989.56K | -2.68M | -5.78M | -2.28M | -379.86K | -1.47M | -1.06M |
| Operating Income Ratio | -440.37% | -332.56% | -3,179.32% | -6,188.25% | -10,567.28% | -71,930.07% | -6,371.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,857.63% | -881.85% |
| Total Other Income/Expenses | 539.16K | 15.09K | -2.40M | 179.74K | 1.10M | 213.72K | 497.87K | 6.04M | -27.91M | -27.51M | -2.87M | -373.57K | 607.92K | -1.15M | -268.53K | -695.52K | -1.38M | -416.14K | 29.69K | 0.00 | 0.00 | 0.00 | -4.68K | 460.51K | -62.80K |
| Income Before Tax | -14.04M | -29.93M | -41.88M | -28.71M | -21.43M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Income Before Tax Ratio | -424.09% | -332.40% | -3,372.68% | -6,149.74% | -10,050.92% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| Income Tax Expense | 3.68K | -15.09K | -5.70K | -179.74K | -1.10M | -213.72K | -680.93K | -6.04M | 27.90M | 26.94M | 466.28K | -1.11M | -1.29M | -93.84K | 4.46M | 2.20M | 3.89M | 1.30M | 989.56K | 2.68M | 5.78M | 2.28M | 384.54K | 1.29M | 1.13M |
| Net Income | -14.05M | -29.92M | -41.87M | -28.53M | -20.33M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Net Income Ratio | -424.20% | -332.23% | -3,372.22% | -6,111.23% | -9,534.57% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| EPS | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.56 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| EPS Diluted | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.31 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Weighted Avg Shares Out | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 688.99K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 742.10K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential
Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential
10 Reddit Penny Stocks Seeing the Most Chatter Today
Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development...
MRKR Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Marker Therapeutics, Inc. (NASDAQ: MRKR) has increased by over 15% pre-market. This is why it happened.
MRKR Stock Price Increased 34.44%: Why It Happened
The stock price of Marker Therapeutics Inc. (NASDAQ: MRKR) increased by 34.44% on March 19. This is why it happened.
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive...
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis announced positive results for the Phase 3 study of Rubraca in...
MRKR Stock Price Increases Over 20% Pre-Market: Why It Happened
The stock price of TapImmune Inc. (NASDAQ: MRKR) increased by over 20% pre-market. This is why it happened.
Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock
HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the closing of an underwritten...
Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference
HOUSTON, March 15, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief...
Source: https://incomestatements.info
Category: Stock Reports